New injection aims to tame kidney disease
NCT ID NCT06830395
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 39 times
Summary
This Phase 2 trial tests an injection called CM313 in 106 people with IgA nephropathy, a kidney disease. The study looks at safety and whether the drug can help control the disease. Participants will receive either CM313 or a placebo, and researchers will monitor side effects and kidney function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CM313 injection
What this could lead to
If successful, this could point toward a new treatment option to control IgA nephropathy and slow kidney damage.
What could go wrong
This is an early Phase 2 trial with only 106 people, so results may not apply to everyone. The drug may cause side effects or not work better than placebo.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.